Cosmo and Glenmark receives market authorization of Winlevi in Europe
Winlevi is authorized in EU for the treatment of acne vulgaris
Winlevi is authorized in EU for the treatment of acne vulgaris
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Subscribe To Our Newsletter & Stay Updated